By Kao Shih-ching / Staff reporterTaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) on Thursday last week said that it expects sales in China to grow next year, when its oral formulation of antibiotic Taigexyn is to be included in China’s national medical insurance program. “This result from negotiations signals that the [Chinese] National Healthcare Security Administration has a high opinion of our drug,” TaiGen chairman Philip Huang (黃國龍) said. Although people in China have had to pay the full price for Taigexyn this year, demand has been robust, he said, adding that cumulative sales of the tablets have increased 1.7 times in the first three quarters of this year. The potential market for Taigexyn is forecast to total 1 billion yuan per year in China, given that a rival treatment, Bayer AG’s Moxifloxacin, reported annual sales of at least 5 billion yuan, TaiGen said. TaiGen shares advanced 4.15 percent to close at NT$21.35 in Taipei trading on Friday, compared with the Taipei Exchange’s decline of 0.81 percent, the exchange’s data showed.

Source: Taipei Times December 01, 2019 15:56 UTC